IDEC Obtains Summary Judgment In Zevalin Suit

Law360, New York (October 16, 2003, 12:00 AM EDT) -- IDEC Pharmaceuticals Corporation was granted summary judgment in its favor by the United States District Court for the Southern District of California, the company said in a statement released Thursday.

The order, signed by a United States District Judge, found that the four patents asserted by defendants Corixa Corporation, Coulter Corporation, the Regents of the University of Michigan and GlaxoSmithKline against IDEC's Zevalin(R) Therapy Regimen were "unenforceable due to the inventors' inequitable conduct in the prosecution of the underlying patent applications," according to IDEC.

Corixa said...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.